HRTX
Heron Therapeutics, Inc.
Price Chart
Latest Quote
$0.43
+0.01 (+3.51%)
Current Price
| Previous Close | $0.42 |
| Open | $0.41 |
| Day High | $0.46 |
| Day Low | $0.41 |
| Volume | 3,620,726 |
Stock Information
| Shares Outstanding | 189.28M |
| Total Debt | $141.63M |
| Cash Equivalents | $44.78M |
| Revenue | $150.71M |
| Net Income | $-30.94M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $82.01M |
| EPS (TTM) | $-0.18 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $180.33M |
| Sales | $150.71M |
| Income | $-30.94M |
| Book/sh | $0.04 |
| Cash/sh | $0.24 |
| Employees | 128 |
Financial Ratios
| Quick Ratio | 1.42 |
| Current Ratio | 2.53 |
| Debt/Eq | 1550.12 |
Returns & Margins
| ROA | -2.71% |
| Gross Margin | 62.80% |
| Operating Margin | -13.73% |
| Profit Margin | -20.53% |
Ownership
| Insider Ownership | 0.90% |
| Institutional Ownership | 83.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 0.54 |
| P/B | 10.08 |
Analyst Data
| Recommendation | none |
| Target Price | $3.00 |
Technical Indicators
| SMA20 | $0.51 |
| SMA50 | $0.83 |
| SMA200 | $1.10 |
| RSI | 46.83 |
| ATR | 0.0368 |
| Shares Float | 135.46M |
| Short Float | 27.05% |
| Short Ratio | 17.93 |
| Volatility | 1.57 |
| Rel Volume | 0.74 |
Performance History
| Week | +14.03% |
| Month | -49.62% |
| Quarter | -42.99% |
| 6 Months | -66.67% |
| YTD | -65.61% |
| Year | -79.46% |
| 3 Years | -64.19% |
| 5 Years | -97.25% |
| 10 Years | -97.52% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.43 | 3,620,726 |
| 2026-06-23 | $0.42 | 2,893,200 |
| 2026-06-22 | $0.43 | 4,814,200 |
| 2026-06-18 | $0.42 | 5,463,100 |
| 2026-06-17 | $0.39 | 3,371,100 |
| 2026-06-16 | $0.38 | 2,824,000 |
| 2026-06-15 | $0.40 | 3,952,900 |
| 2026-06-12 | $0.40 | 4,557,600 |
| 2026-06-11 | $0.41 | 5,242,900 |
| 2026-06-10 | $0.41 | 4,127,800 |
| 2026-06-09 | $0.40 | 4,387,500 |
| 2026-06-08 | $0.45 | 2,595,800 |
| 2026-06-05 | $0.43 | 4,394,500 |
| 2026-06-04 | $0.48 | 5,002,800 |
| 2026-06-03 | $0.45 | 10,825,500 |
| 2026-06-02 | $0.45 | 22,019,300 |
| 2026-06-01 | $0.83 | 2,639,300 |
| 2026-05-29 | $0.87 | 1,828,500 |
| 2026-05-28 | $0.89 | 1,704,100 |
| 2026-05-27 | $0.91 | 1,645,800 |
| 2026-05-26 | $0.88 | 1,606,300 |
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
đ° Latest News
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
Stocktwits âĸ 2026-06-03T03:04:14Z
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires âĸ 2026-06-02T19:45:10ZWhy Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
Insider Monkey âĸ 2026-05-19T11:08:32Z
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges
GuruFocus.com âĸ 2026-05-12T07:02:40ZHeron Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-11T20:51:57Z
Heron Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-11T15:07:18Z
Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline
InvestorsHub âĸ 2026-05-11T15:03:14Z
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks âĸ 2026-05-11T13:30:03Z
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-11T13:10:03Z
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-07T12:50:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $41,347,000 | $38,648,000 | $65,105,000 | $54,874,000 |
| Cost Of Revenue | $41,347,000 | $38,648,000 | $65,105,000 | $54,874,000 |
| Total Revenue | $154,904,000 | $144,285,000 | $127,044,000 | $107,672,000 |
| Operating Revenue | $154,904,000 | $144,285,000 | $127,044,000 | $107,672,000 |
| Expenses | ||||
| Interest Expense | $9,605,000 | $6,032,000 | $3,868,000 | $2,474,000 |
| Total Expenses | $157,442,000 | $155,813,000 | $237,659,000 | $282,330,000 |
| Other Income Expense | $-10,000,000 | $430,000 | $560,000 | $-6,530,000 |
| Other Non Operating Income Expenses | $1,339,000 | $430,000 | $560,000 | $-6,530,000 |
| Net Non Operating Interest Income Expense | $-7,657,000 | $-2,482,000 | $-504,000 | $-836,000 |
| Interest Expense Non Operating | $9,605,000 | $6,032,000 | $3,868,000 | $2,474,000 |
| Operating Expense | $116,095,000 | $117,165,000 | $172,554,000 | $227,456,000 |
| Selling And Marketing Expense | $49,061,000 | $47,085,000 | $67,643,000 | $82,513,000 |
| General And Administrative Expense | $54,605,000 | $53,397,000 | $65,778,000 | $62,239,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Net Interest Income | $-7,657,000 | $-2,482,000 | $-504,000 | $-836,000 |
| Interest Income | $1,948,000 | $3,550,000 | $3,364,000 | $1,638,000 |
| Normalized Income | $-8,856,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Net Income From Continuing And Discontinued Operation | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Total Operating Income As Reported | $-2,538,000 | $-11,528,000 | $-110,615,000 | $-174,658,000 |
| Net Income Common Stockholders | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Net Income | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Net Income Including Noncontrolling Interests | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Net Income Continuous Operations | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Pretax Income | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Special Income Charges | $-11,339,000 | $0 | $0 | - |
| Interest Income Non Operating | $1,948,000 | $3,550,000 | $3,364,000 | $1,638,000 |
| Operating Income | $-2,538,000 | $-11,528,000 | $-110,615,000 | $-174,658,000 |
| Gross Profit | $113,557,000 | $105,637,000 | $61,939,000 | $52,798,000 |
| Per Share | ||||
| Diluted EPS | $-0.12 | $-0.09 | $-0.80 | $-1.67 |
| Basic EPS | $-0.12 | $-0.09 | $-0.80 | $-1.67 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $3,063,000 | $-5,056,000 | $-103,792,000 | $-176,661,000 |
| Total Unusual Items | $-11,339,000 | $0 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-11,339,000 | $0 | $0 | - |
| Reconciled Depreciation | $2,314,000 | $2,492,000 | $2,899,000 | $2,889,000 |
| EBITDA (Bullshit earnings) | $-8,276,000 | $-5,056,000 | $-103,792,000 | $-176,661,000 |
| EBIT | $-10,590,000 | $-7,548,000 | $-106,691,000 | $-179,550,000 |
| Diluted Average Shares | $166,707,000 | $152,449,000 | $138,135,000 | $108,996,407 |
| Basic Average Shares | $166,707,000 | $152,449,000 | $138,135,000 | $108,996,407 |
| Diluted NI Availto Com Stockholders | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Other Special Charges | $11,339,000 | - | - | - |
| Research And Development | $12,429,000 | $16,683,000 | $39,133,000 | $82,704,000 |
| Selling General And Administration | $103,666,000 | $100,482,000 | $133,421,000 | $144,752,000 |
| Other Gand A | $54,605,000 | $53,397,000 | $65,778,000 | $62,239,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $14,333,000 | $-33,651,000 | $-33,973,000 | $13,572,000 |
| Total Assets | $255,877,000 | $233,147,000 | $222,506,000 | $250,951,000 |
| Total Non Current Assets | $17,811,000 | $24,133,000 | $33,732,000 | $45,516,000 |
| Other Non Current Assets | $5,408,000 | $6,483,000 | $8,128,000 | $15,711,000 |
| Current Assets | $238,066,000 | $209,014,000 | $188,774,000 | $205,435,000 |
| Other Current Assets | $9,102,000 | $17,690,000 | $6,118,000 | $13,961,000 |
| Inventory | $92,746,000 | $53,160,000 | $42,110,000 | $54,573,000 |
| Receivables | $89,587,000 | $78,881,000 | $60,137,000 | $52,049,000 |
| Accounts Receivable | $89,587,000 | $78,881,000 | $60,137,000 | $52,049,000 |
| Cash Cash Equivalents And Short Term Investments | $46,631,000 | $59,283,000 | $80,409,000 | $84,852,000 |
| Cash And Cash Equivalents | $28,647,000 | $25,802,000 | $28,677,000 | $15,364,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $111,991,000 | $148,924,000 | $145,076,000 | $133,920,000 |
| Total Debt | $140,638,000 | $177,763,000 | $179,628,000 | $157,477,000 |
| Long Term Debt And Capital Lease Obligation | $140,638,000 | $174,726,000 | $176,553,000 | $154,783,000 |
| Long Term Debt | $140,638,000 | $174,726,000 | $173,753,000 | $149,284,000 |
| Current Debt And Capital Lease Obligation | - | $3,037,000 | $3,075,000 | $2,694,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $241,544,000 | $266,798,000 | $256,479,000 | $237,379,000 |
| Total Non Current Liabilities Net Minority Interest | $145,446,000 | $175,341,000 | $176,794,000 | $155,024,000 |
| Other Non Current Liabilities | $4,808,000 | $615,000 | $241,000 | $241,000 |
| Current Liabilities | $96,098,000 | $91,457,000 | $79,685,000 | $82,355,000 |
| Payables And Accrued Expenses | $87,484,000 | $80,457,000 | $68,757,000 | $68,379,000 |
| Interest Payable | $904,000 | $237,000 | $412,000 | $94,000 |
| Payables | $8,994,000 | $11,709,000 | $3,799,000 | $3,588,000 |
| Accounts Payable | $8,994,000 | $11,709,000 | $3,799,000 | $3,588,000 |
| Equity | ||||
| Common Stock Equity | $13,283,000 | $-33,651,000 | $-33,973,000 | $13,572,000 |
| Preferred Stock Equity | $1,050,000 | - | - | - |
| Total Equity Gross Minority Interest | $14,333,000 | $-33,651,000 | $-33,973,000 | $13,572,000 |
| Stockholders Equity | $14,333,000 | $-33,651,000 | $-33,973,000 | $13,572,000 |
| Gains Losses Not Affecting Retained Earnings | $4,000 | $13,000 | $13,000 | $-19,000 |
| Other Equity Adjustments | $4,000 | $13,000 | $13,000 | $-19,000 |
| Retained Earnings | $-1,939,789,000 | $-1,919,594,000 | $-1,906,014,000 | $-1,795,455,000 |
| Other | ||||
| Ordinary Shares Number | $188,314,430 | $152,127,878 | $150,285,044 | $119,155,000 |
| Share Issued | $188,314,430 | $152,127,878 | $150,285,044 | $119,155,000 |
| Tangible Book Value | $13,283,000 | $-33,651,000 | $-33,973,000 | $13,572,000 |
| Invested Capital | $153,921,000 | $141,075,000 | $139,780,000 | $162,856,000 |
| Working Capital | $141,968,000 | $117,557,000 | $109,089,000 | $123,080,000 |
| Capital Lease Obligations | $0 | $3,037,000 | $5,875,000 | $8,193,000 |
| Total Capitalization | $154,971,000 | $141,075,000 | $139,780,000 | $162,856,000 |
| Additional Paid In Capital | $1,951,185,000 | $1,884,409,000 | $1,870,525,000 | $1,807,855,000 |
| Capital Stock | $2,933,000 | $1,521,000 | $1,503,000 | $1,191,000 |
| Common Stock | $1,883,000 | $1,521,000 | $1,503,000 | $1,191,000 |
| Preferred Stock | $1,050,000 | $0 | $0 | $0 |
| Current Capital Lease Obligation | $0 | $3,037,000 | $3,075,000 | $2,694,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,614,000 | $7,963,000 | $7,853,000 | $11,282,000 |
| Current Accrued Expenses | $78,490,000 | $68,748,000 | $64,958,000 | $64,791,000 |
| Net PPE | $12,403,000 | $17,650,000 | $25,604,000 | $29,805,000 |
| Accumulated Depreciation | $-12,880,000 | $-17,847,000 | $-17,028,000 | $-14,293,000 |
| Gross PPE | $25,283,000 | $35,497,000 | $42,632,000 | $44,098,000 |
| Leases | $0 | $307,000 | $647,000 | $647,000 |
| Other Properties | $25,089,000 | $33,129,000 | $39,465,000 | $40,963,000 |
| Machinery Furniture Equipment | $194,000 | $2,061,000 | $2,520,000 | $2,488,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $6,883,000 | $6,237,000 | $9,917,000 | $18,713,000 |
| Work In Process | $26,613,000 | $27,190,000 | $14,550,000 | $20,723,000 |
| Raw Materials | $59,250,000 | $19,733,000 | $17,643,000 | $15,137,000 |
| Other Short Term Investments | $17,984,000 | $33,481,000 | $51,732,000 | $69,488,000 |
| Long Term Capital Lease Obligation | - | $0 | $2,800,000 | $5,499,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-27,908,000 | $-24,235,000 | $-60,334,000 | $-148,737,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-27,591,000 | $-22,529,000 | $-58,789,000 | $-146,912,000 |
| Cash Flow From Continuing Operating Activities | $-27,591,000 | $-22,529,000 | $-58,789,000 | $-146,912,000 |
| Operating Gains Losses | $11,753,000 | $4,382,000 | $627,000 | $283,000 |
| Investing Activities | ||||
| Capital Expenditure | $-317,000 | $-1,706,000 | $-1,545,000 | $-1,825,000 |
| Investing Cash Flow | $16,009,000 | $18,714,000 | $17,995,000 | $-3,324,000 |
| Cash Flow From Continuing Investing Activities | $16,009,000 | $18,714,000 | $17,995,000 | $-3,324,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $26,169,000 | $0 | $29,755,000 | $75,145,000 |
| Financing Cash Flow | $14,427,000 | $940,000 | $54,107,000 | $75,059,000 |
| Cash Flow From Continuing Financing Activities | $14,427,000 | $940,000 | $54,107,000 | $75,059,000 |
| Net Preferred Stock Issuance | $7,862,000 | $0 | $0 | - |
| Preferred Stock Issuance | $7,862,000 | $0 | $0 | - |
| Net Common Stock Issuance | $18,307,000 | $0 | $29,755,000 | $75,145,000 |
| Common Stock Issuance | $18,307,000 | $0 | $29,755,000 | $75,145,000 |
| Other | ||||
| Repayment Of Debt | $-150,000,000 | $0 | $0 | - |
| Issuance Of Debt | $137,245,000 | $0 | $24,350,000 | $0 |
| Interest Paid Supplemental Data | $6,512,000 | $4,860,000 | $3,059,000 | $2,250,000 |
| End Cash Position | $28,647,000 | $25,802,000 | $28,677,000 | $15,364,000 |
| Beginning Cash Position | $25,802,000 | $28,677,000 | $15,364,000 | $90,541,000 |
| Changes In Cash | $2,845,000 | $-2,875,000 | $13,313,000 | $-75,177,000 |
| Proceeds From Stock Option Exercised | $1,013,000 | $940,000 | $2,000 | $-86,000 |
| Net Issuance Payments Of Debt | $-12,755,000 | $0 | $24,350,000 | $0 |
| Net Long Term Debt Issuance | $-12,755,000 | $0 | $24,350,000 | $0 |
| Long Term Debt Payments | $-150,000,000 | $0 | $0 | - |
| Long Term Debt Issuance | $137,245,000 | $0 | $24,350,000 | $0 |
| Net Investment Purchase And Sale | $16,228,000 | $20,393,000 | $19,527,000 | $-1,726,000 |
| Sale Of Investment | $67,014,000 | $123,480,000 | $107,185,000 | $143,957,000 |
| Purchase Of Investment | $-50,786,000 | $-103,087,000 | $-87,658,000 | $-145,683,000 |
| Net PPE Purchase And Sale | $-219,000 | $-1,679,000 | $-1,532,000 | $-1,598,000 |
| Sale Of PPE | $98,000 | $27,000 | $13,000 | $227,000 |
| Purchase Of PPE | $-317,000 | $-1,706,000 | $-1,545,000 | $-1,825,000 |
| Change In Working Capital | $-31,880,000 | $-27,603,000 | $16,790,000 | $-10,506,000 |
| Change In Payables And Accrued Expense | $9,000,000 | $12,118,000 | $-3,011,000 | $11,225,000 |
| Change In Accrued Expense | $11,715,000 | $3,649,000 | $-3,026,000 | $11,803,000 |
| Change In Payable | $-2,715,000 | $8,469,000 | $15,000 | $-578,000 |
| Change In Account Payable | $-2,715,000 | $8,469,000 | $15,000 | $-578,000 |
| Change In Prepaid Assets | $878,000 | $-9,927,000 | $15,426,000 | $1,010,000 |
| Change In Inventory | $-31,052,000 | $-11,050,000 | $12,463,000 | $-6,191,000 |
| Change In Receivables | $-10,706,000 | $-18,744,000 | $-8,088,000 | $-16,550,000 |
| Changes In Account Receivables | $-10,706,000 | $-18,744,000 | $-8,088,000 | $-16,550,000 |
| Other Non Cash Items | $817,000 | $961,000 | $339,000 | $202,000 |
| Stock Based Compensation | $10,339,000 | $12,962,000 | $32,854,000 | $42,980,000 |
| Amortization Of Securities | $-739,000 | $-2,143,000 | $-1,739,000 | $-736,000 |
| Depreciation Amortization Depletion | $2,314,000 | $2,492,000 | $2,899,000 | $2,889,000 |
| Depreciation And Amortization | $2,314,000 | $2,492,000 | $2,899,000 | $2,889,000 |
| Gain Loss On Sale Of PPE | $414,000 | $4,382,000 | $627,000 | $283,000 |
| Net Income From Continuing Operations | $-20,195,000 | $-13,580,000 | $-110,559,000 | $-182,024,000 |
| Asset Impairment Charge | - | - | $617,000 | $209,000 |
Fetched: 2026-06-16